FDA holds back on J&J schizophrenia drug

Johnson & Johnson will have to provide the FDA with more information about its candidate schizophrenia drug paliperidone palmitate before it gets approval, the company announced yesterday. J&J's Janssen will market the drug. While J&J did not disclose the specifics of the FDA request, the company did say it will not have to perform any additional studies on the drug and that it intends to comply with FDA and provide the requested information. Release [1]